Physical examination, diagnostic tests, laboratory tests: Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
Personal history, questionnaire: Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
Study summary
The SCCSS-FollowUp is a national, multicenter cohort study designed to investigate late effects in childhood cancer survivors in a prospective and longitudinal way. The study is embedded in regular follow-up care and inclusion in the study takes place in a step-wise approach. The investigators collect data from clinical examinations, laboratory and functional tests, and questionnaires to learn more about late effects of childhood cancer treatments.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
This prospective cohort study is based on the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumors or Langerhans cell histiocytosis.
Inclusion Criteria:
* Registered in the Childhood Cancer Registry (ChCR) or treated and followed-up in a Swiss pediatric oncology (SPOG) clinic, but not registered in the ChCR because of residency in neighboring countries
* Diagnosed at age 0 - 20 years
* Childhood cancer treatment completed
* All age categories at time of inclusion in the study (children, adolescents, adults)
* Written informed consent
Exclusion criteria:
* Childhood cancer survivors in a palliative or relapsed situation where no follow-up examinations are foreseen.
Primary outcome measure(s)
Symptoms of organ-specific late effects (example of pulmonary late effects) — At baseline Number of people with cough or shortness of breath when at risk for pulmonary late effects
Signs of organ-specific late effects (example of pulmonary late effects) — At baseline Number of people with signs of disturbed breathing or abnormal breathing sounds when at risk for pulmonary late effects
Tests to assess organ-specific late effects (example of pulmonary late effects) — At baseline Number of people with abnormal pulmonary function testing (e.g. spirometry, body plethysmography) when at risk for pulmonary late effects
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
